TLR7 and colorectal carcinoma: Combining oxaliplatin with TLR agonists R848 reversed the functional orientation of MDSCs towards M1-like macrophages and strengthened oxaliplatin’s antitumor effect, indicating that TLR7/8 agonists have great potential as a new immunologic adjuvant in chemotherapy for oxaliplatin-resistant CRC [58].